Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Innovation Council · Finished

RESPIRE Development of the first oral disease-modifying treatment for chronic obstructive pulmonary disease (COPD)

Coordinator
Palo Biofarma SL, Spain
Runs
1 January 2022 to 30 June 2024
Status
Finished
EU funding
€2.5m
Total cost
€3.5m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190151672

What the project is doing

In the project's own words, from its summary on CORDIS.

Palobiofarma is a Spanish biotech company with the ambition to develop new treatments for cancer and autoimmune diseases based on adenosine receptor modulation. Our compound PBF-680 is a first-in-class therapy with disease modifying effects in respiratory diseases like COPD. Over 65M patients suffer from COPD, yet there are no approved therapies that target disease progression. PBF-680 is a unique molecule designed to specifically antagonise the Adenosine 1 Receptor (A1R). it has shown to be safe and well-tolerated in phase 1 trials and demonstrated to reduce pulmonary symptoms and inflammation in mild-to-moderate asthmatics in phase 2 trials.

With funding from the EIC Accelerator, we will demonstrate efficacy in a phase 2 trial in COPD, a market with high unmet medical need. Proven clinical efficacy will be the major milestone to raise 30M (incl 15M EIC Equity) for a phase 3 trial, followed by an additional fund raising or IPO to independently reach market launch with PBF-680.

Topics

Who is involved

OrganisationCityCountryRole
Palo Biofarma SLMataroSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI